Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer and the third most cancer-related cause of death worldwide. Hepatectomy is considered as the first-line treatment for early-and middle-stage liver cancer. However, the 5-year recurrence rate is as high as 70%-80%, and the median survival time is approximately 2 years. Among multiple prognostic factors, increasing studies have shown that microvascular invasion (MVI) is a high risk factor for postoperative recurrence and metastasis of liver cancer, and it is also an independent risk factor for postoperative recurrence-free survival (RFS) and overall survival (OS) of patients with liver cancer. Therefore, it is of significance to explore effective postoperative adjuvant treatment, thereby delaying the recurrence time and lowering the recurrence rate. In this article, research progress in clinical application of hepatic arterial infusion chemotherapy (HAIC), targeted therapy, immunotherapy and common postoperative approaches combined with TACE in patients with liver cancer complicated with MVI was reviewed, aiming to provide reference for clinical practice.